Exicure set for best day on deal for rare neurodegenerative disorder drugs
Brief: Ipsen and U.S. peer Exicure: collaboration targeting rare neurodegenerative disorders
Brief: Exicure Announces Appointment Of Brian Bock As CFO
Exicure Inc reports results for the quarter ended in March - Earnings Summary
Brief: Exicure, Inc. Reports First Quarter 2021 Financial Results And Corporate Progress
Brief: Twc Enterprises Q1 Earnings Per Share $0.02
Brief: Exicure Reports Full Year 2020 Financial Results And Corporate Progress
U.S. STOCKS ON THE MOVE-Ovid Therapeutics, Riot Blockchain, KemPharm Inc, Genetic Tech
Exicure Inc: Rises on FDA orphan drug tag for skin cancer treatment
Brief: Exicure Granted Orphan Drug Designation By U.S. Food And Drug Administration For Cavrotolimod
U.S. STOCKS ON THE MOVE-Boeing, Tesla, Twitter, GeoVax
U.S. STOCKS ON THE MOVE-Crocs, Eli Lilly, Tesla, Albemarle
U.S. STOCKS ON THE MOVE-Oil stocks, Boeing, GameStop, Twitter, Eli Lilly
Exicure: Gains on fast-track tag for potential skin cancer drug
Brief: Exicure Granted Two Fast Track Designations For Cavrotolimod From The U.S. Food And Drug Administration
Brief: Exicure Announces Appointment Of James Sulat To Board Of Directors
Brief: Exicure Files For Mixed Shelf Offering Of Up To $150 Million - SEC Filing
Brief: Exicure Announces Issuance Of Two New U.S. Patents And A New Patent Allowance Covering Cavrotolimod Through 2034
Brief: Exicure Inc Reports Third Quarter 2020 Financial Results And Corporate Progress